<DOC>
	<DOCNO>NCT02010242</DOCNO>
	<brief_summary>NADPH oxidase enzyme ( NOX ) implicate development several diabetic complication include diabetic nephropathy . GKT137831 first class NOX1/4 inhibitor . The primary objective study evaluate efficacy oral GKT137831 patient residual albuminuria despite maximal inhibition renin angiotensin aldosterone system .</brief_summary>
	<brief_title>Safety Efficacy Oral GKT137831 Patient With Type 2 Diabetes Albuminuria</brief_title>
	<detailed_description>A double-blind , placebo-controlled , randomize , multicenter , parallel group Phase 2 study assess 12-week period treatment oral GKT137831 administer addition standard care patient type 2 diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<criteria>Key Male female age 18 80 year History type 2 diabetes , define fast plasma glucose ≥7.0 mmol/L ( 126 mg/dL ) glycated hemoglobin ( HbA1c ) &gt; 6.5 % ( 48 mmol/mol ) least 2 occasion prior screen . Albuminuria define UACR 300 3500 mg/g . An eGFR ≥30 mL/min/1.73 m2 , calculate CKDEPI formula . Must take ACEI ARB least 6 week prior first screen visit ( Visit 1 ) screening period . The dose must stable least 4 week prior first screen visit ( Visit 1 ) . Combination therapy associate ACEI ARB permit . Key History type 1 diabetes Any nondiabetic kidney disease ( ) except hypertensive nephropathy acceptable . Diagnostic interventional procedure require contrast agent within 4 week first screen visit ( Visit 1 ) plan study . History renal transplant plan renal transplant study . A history acute renal dialysis acute kidney injury ( define accord Kidney Disease : Improving Global Outcomes [ KDIGO ] definition ) within 12 week first screen visit ( Visit 1 ) HbA1c level &gt; 11 % ( 97 mmol/mol ) . History hypothyroidism require hormone replacement therapy . History active cardiovascular disease A personal family history long QT syndrome . Administration investigational product within 30 day within 5 halflives investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Proteinuria</keyword>
	<keyword>Albuminuria</keyword>
</DOC>